Bryan Medical, Inc. appears in FDA premarket notification records as the applicant behind the Tenax Laser Resistant Endotracheal Tube, filed under product codes BTR and BSK and reviewed by the Anesthesiology panel. The most recent clearance in the linked records is K251794, decided September 3, 2026 as substantially equivalent, with a Traditional review and no third-party review. Earlier Tenax clearances in the same record set date to 2020 and 2021, giving the product line a documented filing history across several submissions. [1][2][4][5][6]
The K251794 clearance and its scope
K251794 was received June 12, 2025 and decided September 3, 2026 with decision code SESE, meaning substantially equivalent, under regulation number 21 CFR 868.5730 for tracheal tubes in Class II. The FDA record lists product codes BTR and BSK, a Traditional clearance type, no third-party review, no combination product status and no authorized predetermined change control plan. The applicant address on the filing is 6100 Wooster Pike, Cincinnati, Ohio, and the correspondence was directed to a regulatory consultant at AlvaMed, Inc. in Needham, Massachusetts. [1][2][4]
The decision letter describes packaging as a pouch and chipboard unit box, with five unit boxes in a corrugated shipping box, and states that packaging materials and sizes match the predicate device, with tabs relocated to accommodate a larger size and packaging testing showing no impact to safety or effectiveness. It also states that both devices are laser resistant endotracheal tubes sharing an identical indication for use and intended for use in the same manner. [2]
Device design as published by the manufacturer
Bryan Medical's product page describes Tenax™ as carrying an aluminum wrapped, reinforced spiral shaft running the length of the tube, DualCuffs™ for additional protection against airway fires, and a smooth silicone sheath intended to help minimize damage to vocal cords and surrounding anatomy. The same page lists otolaryngologists, head and neck surgeons, anesthesiologists and multidisciplinary airway teams as common users of laser resistant endotracheal tubes in laser-assisted upper airway procedures. A separate Bryan Medical page describes Tenax® as latex free with the same shaft, cuff and sheath features. [3][7]
The 2021 Tenax decision letter, K213028, lists shared technological characteristics with its predicate: laser resistance using an inner aluminum scattering layer, an atraumatic outer layer for protection of patient tissue, inflatable cuffs, and internal dye as a warning indicator of device puncture or damage. Laser resistance was the performance data cited in support of that determination. The 2020 letter for K200761 cites dimensional testing as its performance data. [5][6]
Filing history in the linked records
The linked collection holds one 510(k) record, K251794, and its decision count is one substantially equivalent decision; the record sample is the same single entry, so the sample and collection denominators coincide here. That count reflects the filings retrieved as of the snapshot date and is not a measure of total company sales, total portfolio or safety performance. [1]
Two earlier Tenax clearances appear in the numbered FDA records: K200761, dated October 23, 2020 and received October 26, 2020, and K213028, dated September 17, 2021 and received September 21, 2021. Both name Bryan Medical, Inc. as applicant, cite 21 CFR 868.5730 and Class II, and list product codes BTR and BSK, matching the regulatory identity used in K251794. [5][6]
Corporate identity and attribution
Bryan Medical's company page states that it is a member of the SPIGGLE & THEIS Group and describes a mission to provide ENT specialists with medical technologies and professional services. That parent relationship is stated by the manufacturer; the FDA records identify Bryan Medical, Inc. as the legal applicant and do not establish ownership. The Cincinnati address appears in FDA filings and on the manufacturer's pages, but those records do not establish it as a headquarters. [1][3][9]
